NT5E and neoplasm: Another therapeutic strategy using MEDI9447 (MedImmune), a potent selective anti-CD73 human monoclonal antibody, either alone or in combination with the anti-PDL1 durvalumab, has been evaluated in phase 1 clinical trial with several tumor types, including lung cancer.